HealthcareServices

Neuromyelitis Optica Spectrum Disorder Sector Forecast Shows Robust Momentum, Climbing to $3.76 Billion With 8.1% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neuromyelitis optica spectrum disorder market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Neuromyelitis Optica Spectrum Disorder Market?_x000D_

The neuromyelitis optica spectrum disorder market size has experienced robust growth in recent years. It is projected to expand from $2.54 billion in 2025 to $2.76 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. Historically, this growth can be attributed to increasing awareness of nmosd, the early development of immunosuppressive treatments, the initial use of corticosteroids for flare control, the adoption of imaging for differential diagnosis, and the rising identification of aqp4 antibodies._x000D_

_x000D_

The neuromyelitis optica spectrum disorder market is anticipated to exhibit substantial growth over the next few years, reaching $3.76 billion by 2030 with a compound annual growth rate (CAGR) of 8.1%. This projected expansion is primarily driven by factors such as increasing demand for targeted biologics, the ongoing development of MOG-antibody therapies, the broadening scope of advanced diagnostic platforms, rising investment in autoimmune research, and the creation of next-generation immunotherapy solutions. Significant trends expected during this forecast period include the increasing adoption of monoclonal antibody therapies, a growing reliance on advanced imaging techniques for early diagnosis, escalating demand for plasma exchange and immunoglobulin therapy, the expansion of AQP4-positive and MOG-antibody testing, and a heightened focus on relapse prevention and long-term disease management._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=22072&type=smp_x000D_

_x000D_

What Drivers Are Supporting Technological Adoption In The Neuromyelitis Optica Spectrum Disorder Market?_x000D_

The expanding prevalence of multiple sclerosis is anticipated to drive the growth of the neuromyelitis optica spectrum disorder market in the future. This condition is a chronic autoimmune disorder impacting the central nervous system, characterized by inflammation, nerve destruction, and diverse neurological manifestations. The rise in MS cases can be attributed to advancements in diagnostic methods, environmental factors, and genetic susceptibility. Improvements in medical imaging, like MRI, have enabled earlier and more precise identification of the disease, contributing to a noticeable increase in diagnosed individuals. With more people receiving an MS diagnosis, awareness of neurological autoimmune conditions grows, resulting in better diagnostic approaches and enhanced recognition of neuromyelitis optica spectrum disorder. For example, according to the UK-based national charity Multiple Sclerosis Trust, the UK recorded approximately 7,100 new multiple sclerosis cases annually in May 2024, with around 135 individuals being diagnosed with MS every week. Consequently, the growing incidence of multiple sclerosis significantly fuels the expansion of the neuromyelitis optica spectrum disorder market._x000D_

_x000D_

Which Segments Are Contributing To The Growth Of The Neuromyelitis Optica Spectrum Disorder Market?_x000D_

The neuromyelitis optica spectrum disorder market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies_x000D_

2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Other Diagnosis_x000D_

3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types_x000D_

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies: Relapsing NMOSD With AQP4-IgG, Monophasic NMOSD With AQP4-IgG, Severe Optic Neuritis With AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) With AQP4-IgG_x000D_

2) By Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies: NMOSD With Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders_x000D_

_x000D_

Which Trends Are Expected To Influence The Neuromyelitis Optica Spectrum Disorder Market In The Upcoming Years?_x000D_

Leading companies operating in the neuromyelitis optica spectrum disorder market are concentrating on developing innovative products, such as long-acting complement inhibitors, to enhance treatment efficacy and improve patient outcomes. These long-acting complement inhibitors are treatments that suppress the complement system for an extended duration, preventing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD), thereby helping minimize relapses and supporting long-term disease control. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical industry, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval marks Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment. The decision was based on the Phase III CHAMPION-NMOSD trial, where Ultomiris demonstrated a 98.6% reduction in relapse risk over 73 weeks compared to a placebo. Trial participants experienced no relapses, and no new safety concerns were identified._x000D_

_x000D_

Who Are The Major Companies Operating In The Neuromyelitis Optica Spectrum Disorder Market?_x000D_

Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd, Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc, Oregon Health & Science University, Arup Laboratories, Argenx SE, Metropolis Healthcare, Rush University Medical Center, Mitsubishi Tanabe Pharma Corporation, Viela Bio, Alexion Pharmaceuticals, Horizon Therapeutics plc, UCB S.A, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi S.A, Pfizer Inc, Eli Lilly and Company, Immune Pharmaceuticals Inc._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neuromyelitis-optica-spectrum-disorder-global-market-report_x000D_

_x000D_

Which Region Is Anticipated To See The Fastest Growth In The Neuromyelitis Optica Spectrum Disorder Market?_x000D_

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neuromyelitis Optica Spectrum Disorder Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=22072&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neuromyelitis Optica Spectrum Disorder Market 2026, By The Business Research Company#_x000D_

_x000D_

Retinal Disorder Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report_x000D_

_x000D_

Optic Atrophy Management Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report_x000D_

_x000D_